Is Nidan Laborator. overvalued or undervalued?

As of 22 September 2025, the valuation grade for Nidan Laborator. has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently undervalued, with a PE ratio of 13.48, an EV to EBITDA of 7.08, and a Price to Book Value of 0.39. These ratios suggest that the company is trading at a discount compared to its earnings and asset value.
In comparison to its peers, Nidan Laborator. stands out with its low valuation metrics. For instance, Max Healthcare is very expensive with a PE ratio of 94.6, while Apollo Hospitals, which is rated attractive, has a PE ratio of 70.79. This stark contrast highlights Nidan's undervaluation in the market. Additionally, the company's recent stock performance has been lackluster, with a year-to-date return of -34.14%, contrasting with a 6.59% gain in the Sensex, further reinforcing the case for its undervaluation.